Renal ischemia-reperfusion injury (IRI) is a major pathological driver of acute kidney injury (AKI), for which effective therapeutic strategies remain lacking. Recently, novel forms of programmed cell death (PCD), including pyroptosis, ferroptosis, cuproptosis and necroptosis, have been identified as key mediators of tubular damage and inflammation in renal IRI. This review delineates a hierarchically organized and spatiotemporally regulated PCD network, positioning it as a central determinant of cellular fate following renal IRI. We systematically characterize the distinct molecular signatures of each death modality and critically examine their extensive crosstalk within the pathological renal microenvironment. Synthesizing current evidence, we demonstrate that this network operates in a cell type- and phase-specific manner, driving a vicious cycle of inflammation and oxidative stress. Targeting this interconnected network rather than isolated pathways represents a paradigm shift. We critically assess current therapeutic strategies and their limitations in the context of this network. Finally, we propose a forward-looking roadmap that emphasizes combination therapies guided by spatial transcriptomics, patient stratification using PCD-specific biomarkers and the development of smart nanosystems capable of dynamically modulating key network nodes. Deciphering and therapeutically intervening in this PCD network is pivotal for developing effective treatments for renal IRI.